| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 24, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mecha
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, "Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity," and will be presented on June 2. John Yu, M.D., Kairos CEO commented, "We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer tr
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: To our valued stockholders, As we reflect on the Company's progress before and after our initial public offering and listing on the NYSE American stock exchange, I am excited about what the future holds. We currently have two ongoing clinical trials for our lead drug, ENV105, which is being tested in patients with prostate cancer in a Phase 2 trial and is being tested in a Phase 1 trial for patients with a type of lung cancer (called EGFR-dependent non-small cell lung cancer). As part of these trials, we are also identifying and confirming biomarker
8-K - Kairos Pharma, LTD. (0001962011) (Filer)
DEFR14A - Kairos Pharma, LTD. (0001962011) (Filer)
SCHEDULE 13G - Kairos Pharma, LTD. (0001962011) (Subject)
3 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)
4 - Kairos Pharma, LTD. (0001962011) (Issuer)